当前位置: 首页 > 详情页

MicroRNA hsa-miR-29a-3p modulates CYP2C19 in human liver cells

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]US FDA, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA; [2]Capital Med Univ, Beijing Pediat Res Inst, Beijing Childrens Hosp, Beijing Key Lab Pediat Dis Otolaryngol Head & Nec, Beijing 100045, Peoples R China; [3]Arkansas Dept Hlth, Little Rock, AR 72205 USA; [4]Natl Ctr Toxicol Res, 3900 NCTR Rd,HFT 100, Jefferson, AR 72079 USA
出处:
ISSN:

关键词: hsa-miR-29a-3p CYP2C19 Drug metabolizing enzymes Pharmacogenomics Inter-individual variability microRNA

摘要:
Cytochrome P450 2C19 (CYP2C19) is involved in the metabolism of many drugs. Extensive studies have demonstrated that genetic variants and endogenous and environmental factors play important roles in the expression of CYP2C19. However, the role of microRNAs (miRNAs) in controlling CYP2C19 expression has not been investigated completely. In the present study, we performed in silico analysis to rank putative miRNA/CYP2C19 hybrids with regards to the predicted stabilities of their duplexes and then we applied a series of biochemical and molecular assays to elucidate the underlying functional mechanisms for the regulation of CYP2C19 by miRNAs. In silico analysis indicated that hsa-miR-23a-3p and hsa-miR-29a-3p target the coding region of CYP2C19 with hybrid stabilities of -27.5 kcal/mol and -23.3 kcal/mol, respectively. RNA electrophoresis mobility shift assays showed that both hsa-miR-23a-3p and hsa-miR-29a-3p miRNAs were able to bind directly to their cognate targets in the CYP2C19 transcript. Further, a significant inverse correlation was found between chemically-induced up-regulation of hsa-miR-29a-3p and CYP2C19 expression in HepaRG cells. In addition, inverse correlations were also observed in human liver tissue samples between the level of CYP2C19 mRNA expression and both hsa-miR-23a-3p and hsa-miR-29a-3p levels. All these results demonstrated the suppressing role of hsa-miR-29a-3p on CYP2C19 expression. Published by Elsevier Inc.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2014]版:
大类 | 2 区 医学
小类 | 2 区 药学
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 药学
JCR分区:
出版当年[2013]版:
Q1 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2013版] 出版当年五年平均 出版前一年[2012版] 出版后一年[2014版]

第一作者:
第一作者机构: [1]US FDA, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA;
通讯作者:
通讯机构: [1]US FDA, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA; [4]Natl Ctr Toxicol Res, 3900 NCTR Rd,HFT 100, Jefferson, AR 72079 USA
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院